CIAM
PCVX icon

Caitong International Asset Management’s Vaxcyte PCVX Stock Holding History

Caitong International Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,255
Closed -$72.9K – 3350
2026
Q1 		$72.9K Buy
1,255
+425
+51% +$23.1K 0.01% 674
2025
Q4 		$38.3K Buy
830
+789
+1,924% +$35.3K 0.01% 804
2025
Q3 		$1.48K Sell
41
-42
-51% -$1.39K ﹤0.01% 1416
2025
Q2 		$2.7K Sell
83
-20,932
-100% -$686K ﹤0.01% 1279
2025
Q1 		$794K Buy
21,015
+20,720
+7,024% +$1.66M 0.59% 25
2024
Q4 		$24.1K Buy
+295
New +$29.3K 0.02% 731

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caitong International Asset Management's PCVX Position: Q2 2026 in Review

Caitong International Asset Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 1,255 shares — an estimated $72.9K sold.

Caitong International Asset Management first reported a position in PCVX in Q4 2024 and held it in 6 quarters. The position peaked at $794K in Q1 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Caitong International Asset Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 1,255 Vaxcyte shares in Q2 2026, an estimated $72.9K.
  • Caitong International Asset Management first reported a position in Vaxcyte in Q4 2024 and held it in 6 quarters.
  • Caitong International Asset Management's Vaxcyte position peaked at $794K in Q1 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.